Navigation Links
Unique protein bond enables learning and memory
Date:10/30/2012

AUGUSTA, Ga. Two proteins have a unique bond that enables brain receptors essential to learning and memory to not only get and stay where they're needed, but to be hauled off when they aren't, researchers say.

NMDA receptors increase the activity and communication of brain cells and are strategically placed, much like a welcome center, at the receiving end of the communication highway connecting two cells. They also are targets in brain-degenerating conditions such as Alzheimer's and Parkinson's.

In a true cradle-to-grave relationship, researchers have found the scaffolding protein, SAP102, which helps stabilize the receptor on the cell surface, binds with a subunit of the NMDA receptor called GluN2B at two sites, said Dr. Bo-Shiun Chen, neuroscientist at the Medical College of Georgia at Georgia Health Sciences University.

While one binding site is the norm, these proteins have one that's stronger than the other. When it's time for the normal receptor turnover, the stronger bond releases and the lesser one shuttles the receptor inside the cell for degradation or recycling.

"One binding site is involved in stabilizing the receptor on the cell surface and the other is important in removing the receptor. We think it's a paradigm shift; we've never thought about the same scaffolding protein having two roles," said Chen, corresponding author of the study in the journal Cell Reports.

"We believe by understanding the normal turnover of these receptors, we can learn more about how to prevent the abnormal receptor loss that occurs in debilitating diseases such as Alzheimer's." In Parkinson's, the receptors inexplicably move away from where the synapse, or information highway, connects to the neuron, making them less effective. NMDA receptors are supposed to cluster where the synapse hooks into the receiving neuron; in fact, it's part of what anchors the synapse, Chen said.

Interestingly, this pivotal protein, SAP102, a member of the MAGUK family of scaffolding proteins, is the only family member known to directly contribute to maladies: its mutation causes intellectual disability.

While all cells have a system for managing the number of receptors on their surface, in Alzheimer's, this removal process appears accelerated, with increased engulfing of receptors and less neuron-to-neuron communication. The neurotransmitter glutamate helps establish and maintain the synapse and also binds with GluN2B.

GluN2B-containing NMDA receptors stay open to receive information for a long time, enabling the type of vigorous and sustained communication that enables learning and memory. In fact the number of these receptors naturally decreases with age, which may be one reason young people learn easier. When it's time to remove a receptor, phosphorus gets added to GluN2B, changing its function so it no longer binds to the scaffolding protein.


'/>"/>
Contact: Toni Baker
tbaker@georgiahealth.edu
706-721-4421
Georgia Health Sciences University
Source:Eurekalert  

Related medicine news :

1. Moffitt researchers identify unique immune gene signature across thousands of patients solid tumors
2. How is grief unique to young adults with cancer?
3. Kings to develop unique sunscreen with Aethic
4. A CNIO team creates a unique mouse model for the study of aplastic anaemia
5. Moffitt Cancer Center melanoma expert reviews unique adverse events with newly approved drug
6. Brain Scans of Hoarders Show Unique Abnormalities
7. Heat-shock factor reveals its unique role in supporting highly malignant cancers
8. LA BioMed offers unique educational and research opportunity to local high school seniors
9. Unique program bringing electronic medical record data to ambulances lauded
10. FirstVitals Health and Wellness, Inc. awarded $4 Million CMS Innovation Grant for Unique Telehealth Diabetes Progam Focused on Glycemic Control and Prevention of Diabetic Foot Complications
11. Unique physiology key to diagnosing and treating diabetes in Asian populations
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Unique protein bond enables learning and memory
(Date:3/27/2017)... ... 27, 2017 , ... SyncDog, Inc. , the leading ... LG Business Solutions at ATARC Federal Mobile Computing Summit , March 28. ... education and examination into the mobility tools and technology employed by the Federal ...
(Date:3/27/2017)... ... March 27, 2017 , ... M&S Technologies, ... of Conformity for the Smart System® 20/20. CE Certification builds upon M&S's long-standing ... and specifications such as ANSI, ISO and proven test methods used in the ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... sideline athletes. A type of groin injury, it occurs when the muscles around ... intense pain in and around the lower torso, as well as accompanying tenderness ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek ... to pursue the recent RNA methylation “gold rush” with their established portfolio of ... newfound characteristics of N6-methyladenosine, or m6A , RNA methylation has received a ...
(Date:3/27/2017)... ... March 27, 2017 , ... Janet Schloz is still in shock after receiving a ... I’ve had in a long time,” she said. , She thinks the coming week is ... I never thought I would have to help my students.” , The award will allow ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... BOSTON , March 27, 2017 /PRNewswire/ ... company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a ... of innovative therapies based upon tetracycline chemistry, announced ... for the treatment of moderate to severe acne ... is a once-daily, oral, narrow spectrum tetracycline-derived antibiotic ...
(Date:3/27/2017)... -- Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that its Board ... as Impax,s President and Chief Executive Officer and a ... Mr. Bisaro will succeed J. Kevin Buchi , ... Officer since December of 2016. With ... Bisaro, 56, is an accomplished global business leader who ...
(Date:3/27/2017)... , March 27, 2017  PhaseRx, Inc. ... for life-threatening inherited liver diseases in children, today ... full year ended December 31, 2016 and provided ... "PhaseRx continued to make progress during the ... positive results from our non-human primate safety study, and ...
Breaking Medicine Technology: